Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announced today the availability of Developmental Drug Review, a series of competitive analysis reports that profiles and comparatively ranks compounds being developed for central nervous system (CNS) diseases and metabolic disorders. The reports examine key compounds by drug class and provide assessments of their clinical potential, rationales behind the assessments, current developmental status and the status of any licensing agreements.

(Photo: )

Titan Pharmaceuticals, a biopharmaceutical company located in South San Francisco, California, recently reviewed Developmental Drug Review's Parkinson's Disease Drugs.

"The Developmental Drug Review for Parkinson's disease provided us with a consolidated review of publicly available and proprietary data sources in one easy-to-understand book," said Lynne Jacobson, senior director of corporate development at Titan. "The insight that Decision Resources provides in this Parkinson's disease drugs report contributed to our understanding of the product development opportunities in Parkinson's disease."

  Drug classes covered in the Developmental Drug Review series include:   * CNS Disorders    Alzheimer's disease & Dementia drugs    Antiepileptic drugs    Migraine drugs    Multiple sclerosis drugs    Neuroprotectants    Pain drugs    Parkinson's disease       Psychiatric    Antidepressants    Antipyschotic drugs    Anxiolytics    * Metabolic Disorders       Osteoporosis    Bone-forming drugs    Bone resorption inhibitors (HRT)    Bone resorption inhibitors (non-HRT)        Obesity    Obesity (central)    Obesity (peripheral)        Type I & II Diabetes    Cell therapies    Insulin (rapid/short acting)    Insulin (intermediate/long acting)    Insulin sensitizers    Insulin secretagogues    Immunomodulators    Metabolic modulators    About Decision Resources 

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

New HMO Industry Report Finds Overall Enrollment Declined But Many Plans Show Growth

View Now